Last reviewed · How we verify
2,4-Dimethoxy-Beta-Methylcinnamic Acid (DIMECROTIC ACID)
2,4-Dimethoxy-Beta-Methylcinnamic Acid (generic name: DIMECROTIC ACID) is a dimecrotic acid drug. It is currently in Phase 2 development.
DIMECROTIC ACID is thought to work by modulating a specific biological pathway, although the exact mechanism is not well understood.
2,4-Dimethoxy-Beta-Methylcinnamic Acid (DIMECROTIC ACID) is a small molecule drug in the dimecrotic acid class, but its original developer and current owner are unknown. Its target and approved indications are also not specified. The drug's commercial status, including its patent status and generic availability, is unclear. Further research is needed to understand its pharmacokinetic properties, such as half-life and bioavailability. As a result, its safety profile and potential side effects are not well established.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DIMECROTIC ACID |
|---|---|
| Drug class | dimecrotic acid |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have locks on them, and DIMECROTIC ACID is a key that fits into one of those locks. When it binds to the lock, it can either open the lock to allow something in or out, or it can block the lock so nothing can get in or out. This can affect how cells behave and communicate with each other.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 2,4-Dimethoxy-Beta-Methylcinnamic Acid CI brief — competitive landscape report
- 2,4-Dimethoxy-Beta-Methylcinnamic Acid updates RSS · CI watch RSS
Frequently asked questions about 2,4-Dimethoxy-Beta-Methylcinnamic Acid
What is 2,4-Dimethoxy-Beta-Methylcinnamic Acid?
How does 2,4-Dimethoxy-Beta-Methylcinnamic Acid work?
What is the generic name of 2,4-Dimethoxy-Beta-Methylcinnamic Acid?
What drug class is 2,4-Dimethoxy-Beta-Methylcinnamic Acid in?
What development phase is 2,4-Dimethoxy-Beta-Methylcinnamic Acid in?
Related
- Drug class: All dimecrotic acid drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing